Herbal Medicine in the Treatment of Functional Gastrointestinal Disorders: A Systematic Review with Meta-analysis
Overview
Affiliations
Background And Aims: The efficacy of herbal medicines (HMs) for functional gastrointestinal disorders (FGIDs) including irritable bowel syndrome (IBS), functional dyspepsia (FD) and functional constipation (FC) is controversial. A systematic review with meta-analysis was conducted to determine their effectiveness for FGIDs.
Methods: We searched the following electronic databases till July 2019 with English language restriction: The Cochrane Library, EMBASE and PUBMED. Randomized double-blind controlled trials of HMs compared with placebo or conventional pharmacological drugs for adult FGIDs patients were included.
Results: In total, 49 trials involving 7396 participants with FGIDs were included. The risk of bias was low in 9, unclear in 36, and high in 4 trials. More than 33 different herbal formulae were tested. HMs demonstrated statistically significant benefits for symptom improvement compared with placebo in 46 trials (RR = 1.67, 95% CI 1.48-1.88). When compared with conventional pharmacological therapy in 5 trials, HMs were found to be non-inferior (RR = 1.10, 95% CI 1.03-1.18). The number of trials with regards to FD, IBS and FC were 19, 23 and 7 respectively. Subgroup analysis found that HMs were better than placebo in alleviating symptoms for FD (RR = 1.50, 95% CI 1.32-1.69), IBS (RR = 1.62, 95% CI 1.32-1.97) and FC (RR = 3.83, 95% CI 2.26-6.50). HMs tended to have more patients with adverse events than placebo, but similar to conventional pharmacological drugs.
Conclusions: Our findings provide a positive signal for HMs as a potentially well-tolerated and effective treatment for FGIDs, deserving further examination in high-quality trials.
Borewicz K, Zhao Y, Zhu Y Sci Rep. 2024; 14(1):28651.
PMID: 39562633 PMC: 11576911. DOI: 10.1038/s41598-024-79360-9.
Kim M, Park C, Park J, Kim J, Ko S Medicine (Baltimore). 2024; 103(45):e40269.
PMID: 39533605 PMC: 11556985. DOI: 10.1097/MD.0000000000040269.
Pal S, Arisha R, Mazumder P Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(1):25-46.
PMID: 39096376 DOI: 10.1007/s00210-024-03332-z.
Anti-Influenza A Potential of Linn. Extract Based on Bioinformatics Analysis and In Vitro Assays.
Kim M, Nowakowska A, Kim J, Kim Y Int J Mol Sci. 2024; 25(13).
PMID: 39000173 PMC: 11241564. DOI: 10.3390/ijms25137065.
Zhao X, Cheng X, Ye J, Ren J, Li B, Tan D PLoS One. 2024; 19(5):e0301686.
PMID: 38809916 PMC: 11135732. DOI: 10.1371/journal.pone.0301686.